ACHC · Acadia Healthcare Company, Inc.
$27.31
+0.34 (+1.26%)
At close · Aug 21
Market Cap
$2.49B
Shares
92.21M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$26.97
Open$27.00
Day$26.73–27.82
52W close$11.68–35.61
Avg vol 30d2.6M
Short int21.8M · 23.6% float · 6.7d
Short vol65%
Last earningsJul 29, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 28
Up next
Next earnings call
Oct 28, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 28, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+20%
above
Price vs 50-day avg
−9%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
64%
mid-range
Momentum
relative strength
1-month return
−21%
trailing
6-month return
+15%
trailing
YTD return
+90%
this year
Relative strength
+4%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $30 › 200d $22 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +68 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
23.64% of float · ▲ +0.0% MoM · 6.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
315 holders — near 3-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
+5%
Y/Y
EPS growth
−537%
Y/Y
Free cash flow
$-439.9M
Buyback
$250.0M
remaining
Balance sheet
$2.4B
net debt
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 28, 2026
Revenue
· Full Year 2026
Initiated
$3.4B – $3.45B
prior FY $3.31B
midpoint +3.4% Y/Y
Adjusted EBITDA
· Full Year 2026
Non-GAAP
Initiated
$590M – $615M
Operating Cash Flow
· Full Year 2026
Initiated
$350M – $400M
Capital expenditures
· Full Year 2026
Initiated
$235M – $255M
Prior guidance
period ended
· from the 8-K filed Feb 25, 2026
Adjusted EBITDA
· First Quarter 2026
$130M – $137M
Revenue
· First Quarter 2026
$820M – $830M
Startup losses
· First Quarter 2026
$14M
Adjusted earnings per diluted share
· First Quarter 2026
$0.25 – $0.30
Adjusted EBITDA
· First Quarter 2026
$130M – $137M
Adjusted earnings per diluted share
· First Quarter 2026
$0.25 – $0.30
Guided vs delivered
· last 4 settled
Revenue
2025
guided $3.3B – $3.35B
$3.31B
In line
Revenue
2024
guided $3.18B – $3.25B
$3.15B
Miss −1.9%
Revenue
first quarter 2024
guided $775M – $785M
$768.05M
Miss −1.5%
Revenue
full year
guided $2.9B – $2.92B
$2.93B
Beat +0.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+20%
Bullish
Price vs 50-day avg
−9%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
64%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $30 › 200d $22 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +68 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
23.64% of float · ▲ +0.0% MoM · 6.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
315 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $12
Now $27 · 64%
Range high $36
vs 200-day avg +20%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Acute inpatient volumes | 5.5% | second quarter of 2026 | — |
| Acute revenue | $494.6M | second quarter of 2026 | -0.2% |
|
|
|||
| Adjusted EBITDA non-GAAP | $293.4M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted income attributable to Acadia Healthcare Company, Inc. non-GAAP | $35.07M | Three Months Ended June 30, 2026 | — |
| Adjusted income attributable to Acadia Healthcare Company, Inc. per diluted share non-GAAP | $0.38 | Three Months Ended June 30, 2026 | — |
| Beds | 12,600 | As of June 30, 2026 | — |
| Behavioral healthcare facilities operated | 279 | As of June 30, 2026 | — |
| Capital expenditures | $38.6M | second quarter of 2026 | — |
| Comprehensive treatment facility (CTC) revenue | $141.2M | second quarter of 2026 | -0.2% |
|
|
|||
| Employees | 25,000 | As of June 30, 2026 | — |
| Newly licensed beds from newly constructed facilities | 240 | second quarter of 2026 | — |
|
|
|||
| Operating cash flows | $162.1M | second quarter of 2026 | — |
| Patients served daily | 84,000 | As of June 30, 2026 | — |
| Residential treatment facility (RTC) revenue | $96.5M | second quarter of 2026 | — |
| Same Facility Adjusted EBITDA non-GAAP | $400.43M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Same Facility Admissions | 54,141 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Same Facility Average Length of Stay | 14.7 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Same-facility revenue | $856.4M | second quarter of 2026 | — |
|
|
|||
| Specialty treatment facility revenue | $133.5M | second quarter of 2026 | -8.4% |
|
|
|||
| Total Facility Adjusted EBITDA non-GAAP | $373.17M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Total Facility Admissions | 55,173 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Total facility average length of stay | 14.6 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Total Facility Patient Days | 804,970 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Total facility revenue per patient day | $1,076 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted net income attributable to Acadia non-GAAP | $33.3M | first quarter 2026 | — |
| Newly licensed beds | 82 | first quarter 2026 | — |
| Newly licensed beds to existing facilities | 42 | first quarter 2026 | — |
| Patient days | 1.6% | first quarter 2026 | — |
| Revenue per patient day | 5.6% | first quarter 2026 | — |
| Newly licensed beds added | 1,089 | year ended December 31, 2025 | — |
| Same facility revenue increased | 4.4% | fourth quarter of 2025 | — |
| Same facility revenue per patient day | $1,025 | year ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACHC
this stock
Acadia Healthcare Company, Inc.
|
$2.49B | +90.1% | +5.0% | — | 23.6% |
|
HCA
HCA Healthcare, Inc.
|
$90.30B | -13.0% | +7.1% | 14.0 | 2.7% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$30.64B | -4.8% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.98B | +37.2% | +0.9% | 10.5 | 4.0% |
|
FMS
Fresenius Medical Care AG
|
$12.49B | -1.6% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACHC | -10.8% | -20.7% | +15.1% | -9.0% | +90.1% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -8.9% | -24.0% | +3.9% | -11.0% | +78.2% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
—
Spent (derived)
—
Remaining
$250.00M
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.